Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06239194Phase 1Recruiting

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Role: lead

NCT07249905Phase 1Recruiting

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

Role: lead

NCT07110584Phase 1Recruiting

Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors

Role: lead

NCT07445971Phase 1Recruiting

A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.

Role: lead

NCT03705169Phase 1Terminated

Pharmacokinetics and Safety of SAR441236

Role: collaborator

All 5 trials loaded